Skip to main content
BL Pharmtech Corp. logo

BL Pharmtech Corp. — Investor Relations & Filings

Ticker · 065170 ISIN · KR7065170003 KO Manufacturing
Open in API
Filings indexed 278 across all filing types
Latest filing 2024-12-16 Director's Dealing
Country KR South Korea
Listing KO 065170

About BL Pharmtech Corp.

http://www.blpharmtech.com/

BL Pharmtech Corp. is a healthcare company that manufactures, distributes, and sells health functional foods, dietary supplements, and nutraceuticals. The company's portfolio also includes cosmetics, food additives, and pharmaceuticals. A significant part of its operations is dedicated to biotechnology and bio-pharmaceutical research and development. Through its Daedeok Research Institute and in collaboration with subsidiaries BL Melanys and BL Science, the company partners with academic institutions, including KAIST and Columbia University Medical Center, to advance its research initiatives.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by corporate insiders to report changes in their shareholdings. The content details a change in share count due to a 10:1 stock consolidation (reverse split) for an executive (Shin Dong Jin). This falls under the category of Director's Dealing (DIRS), which covers insider share transactions and ownership changes.
2024-12-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a mandatory disclosure by corporate insiders (directors/major shareholders) regarding changes in their shareholdings. In the provided classification schema, this corresponds to 'Director's Dealing' (DIRS), which covers insider transactions and changes in ownership status.
2024-12-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and the Korea Exchange. This is a standard regulatory filing in South Korea used by insiders (directors, executives, and major shareholders) to report changes in their shareholdings. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2024-12-16 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders (Park Young-chul and related parties) in the company 'BL Pharmtech'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks changes in significant ownership levels and voting rights.
2024-12-16 Korean
본점소재지변경
Regulatory Filings Classification · 1% confidence The document is a short, formal regulatory announcement regarding a change in the company's registered office address (headquarters). It does not fit into specific categories like financial reports, dividends, or share transactions. As it is a standard regulatory disclosure of corporate information, it falls under the general regulatory filing category.
2024-12-10 Korean
[기재정정]주요사항보고서(감자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing titled '주요사항보고서(감자 결정)' (Major Report: Capital Reduction Decision) submitted to the Korea Exchange. It details a corporate action regarding a capital reduction (share consolidation) and provides an amendment (정정신고) to the previously filed schedule. Since this relates to a change in capital structure and is a formal regulatory disclosure of a corporate action, it falls under the 'Regulatory Filings' category as it does not fit into more specific categories like 'Share Issue' (which is for new shares) or 'Dividend' announcements.
2024-12-09 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.